The treatment of urinary incontinence with Duloxetine
- 1 January 2008
- journal article
- review article
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 28 (2) , 166-169
Abstract
Duloxetine is a Serotonin and Noradrenaline reuptake inhibitor, and is the first drug licensed for medical treatment of urodynamic stress incontinence. In this paper, we will briefly review the pharmacology, current evidence and controversies in relation to the use of duloxetine.Keywords
This publication has 25 references indexed in Scilit:
- A RANDOMIZED CONTROLLED TRIAL OF DULOXETINE ALONE, PELVIC FLOOR MUSCLE TRAINING ALONE, COMBINED TREATMENT AND NO ACTIVE TREATMENT IN WOMEN WITH STRESS URINARY INCONTINENCEJournal of Urology, 2005
- Reader's guide to critical appraisal of cohort studies: 1. Role and designBMJ, 2005
- The impact of stress urinary incontinence on sexual activity in women.Cleveland Clinic Journal of Medicine, 2005
- The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinenceAmerican Journal of Obstetrics and Gynecology, 2004
- Role of serotonin and noradrenaline in stress urinary incontinenceBJU International, 2004
- Duloxetine: an innovative approach for treating stress urinary incontinenceBJU International, 2004
- Duloxetine vs placebo in the treatment of stress urinary incontinence: a four‐continent randomized clinical trialBJU International, 2004
- Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinenceBJOG: An International Journal of Obstetrics & Gynaecology, 2004
- Sphincteric Urinary Incontinence: Relationship of Vesical Leak Point Pressure, Urethral Mobility and Severity of IncontinenceJournal of Urology, 2003
- Clinical and urodynamic features of intrinsic sphincter deficiencyNeurourology and Urodynamics, 2003